The Cancer Biomarker Panel includes both a Five-Plex assay, which simultaneously measures five serum biomarkers, Macrophage Migration Inhibitory Factor (MIF), Prolactin, CA-125, Leptin and Osteopontin (OPN), and a Single Plex IGF-II assay.
The combination of the six serum biomarkers that discriminate between disease-free and ovarian cancer patients was characterized and validated by Dr. Gil Mor of Yale University. Using a unique algorithm developed by Dr. Mor's Laboratory, the profile of the six biomarkers in circulation was used to detect all stages (I, II, III and IV) of ovarian cancer with high sensitivity and accuracy.
The assays can be used to quantify these biomarkers in serum, plasma, and cell/tissue culture supernatant samples. The kit is for research use only.